[{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calico Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calico Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calico Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calico Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Fosigotifator

Fosigotifator
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

AbbVie Inc

U.S.A

ChemOutsourcing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Fosigotifator

Therapeutic Area : Psychiatry/Psychology

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 01, 2024

Lead Product(s) : Fosigotifator

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Abbvie Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

AbbVie Inc

U.S.A

ChemOutsourcing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Fosigotifator

Therapeutic Area : Genetic Disease

Study Phase : Undisclosed

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Expanded Access to Fosigotifator

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 19, 2024

Lead Product(s) : Fosigotifator

Therapeutic Area : Genetic Disease

Highest Development Status : Undisclosed

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Abbvie Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

AbbVie Inc

U.S.A

ChemOutsourcing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Fosigotifator

Therapeutic Area : Genetic Disease

Study Phase : Phase I/ Phase II

Sponsor : Calico Life Sciences

Deal Size : Inapplicable

Deal Type : Inapplicable

An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 07, 2023

Lead Product(s) : Fosigotifator

Therapeutic Area : Genetic Disease

Highest Development Status : Phase I/ Phase II

Sponsor : Calico Life Sciences

Deal Size : Inapplicable

Deal Type : Inapplicable

Abbvie Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

AbbVie Inc

U.S.A

ChemOutsourcing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Fosigotifator

Therapeutic Area : Neurology

Study Phase : Phase I

Sponsor : Massachusetts General Hospital

Deal Size : Inapplicable

Deal Type : Inapplicable

Investigational Drug ABBV-CLS-7262 Initiates Design Phase For Entry Into The HEALEY ALS Platform Trial

Details : ABBV-CLS-7262 targets eIF2B, a key regulator of the ISR, a pathway activated in people with ALS. In neurons exposed to cellular stressors, inhibition of the ISR by ABBV-CLS-7262 restores protein synthesis and dissolves pre-formed TDP-43 containing stress...

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 07, 2022

Lead Product(s) : Fosigotifator

Therapeutic Area : Neurology

Highest Development Status : Phase I

Sponsor : Massachusetts General Hospital

Deal Size : Inapplicable

Deal Type : Inapplicable

Abbvie Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

05

AbbVie Inc

U.S.A

ChemOutsourcing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Fosigotifator

Therapeutic Area : Neurology

Study Phase : Phase I

Sponsor : Calico Life Sciences

Deal Size : Inapplicable

Deal Type : Inapplicable

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic L...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 02, 2021

Lead Product(s) : Fosigotifator

Therapeutic Area : Neurology

Highest Development Status : Phase I

Sponsor : Calico Life Sciences

Deal Size : Inapplicable

Deal Type : Inapplicable

Abbvie Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

06

Calico Life Sciences

U.S.A

ChemOutsourcing

Not Confirmed

07

Calico Life Sciences

U.S.A

ChemOutsourcing

Not Confirmed